Benchmark Co. analyst Bruce Jackson maintained a Buy rating on Biofrontera today and set a price target of $3.00. The company’s shares closed yesterday at $1.04.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Jackson is an analyst with an average return of -17.5% and a 32.67% success rate. Jackson covers the Healthcare sector, focusing on stocks such as Harvard Bioscience, Biofrontera, and Belite Bio, Inc. ADR.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biofrontera with a $2.00 average price target.
BFRI market cap is currently $10.88M and has a P/E ratio of -0.48.
Read More on BFRI:
Disclaimer & DisclosureReport an Issue
- Biofrontera Inc. price target lowered to $9 from $10 at Roth Capital
- Biofrontera Approves Key Proposals at Special Meeting
- Biofrontera says last patient completes treatment in Phase 3 study of Ameluz
- Biofrontera, Inc. Reports Record Sales Amid Strategic Growth
- Biofrontera announces last-patient-out in Phase 2b study of Ameluz topical gel
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)